FY20 Integrated Performance Report Announces Goal for Carbon Neutrality by FY30, and Outlines Progress on Pay Equity and COVID-19 Response
Oct. 13, 2020 – Global corporate citizenship is instrumental to the work we do and how we operate. With today’s release of the Medtronic Fiscal Year 2020 (FY20) Integrated Performance Report we share our progress in key environmental, social, and governance (ESG) areas. This includes surpassing our FY20 environmental performance goals and setting a goal to go carbon neutral in our operations by FY30; achieving 100% global gender pay equity in many countries including the United States; and increasing global access to ventilators and other technology to aid in COVID-19 response.
“As stewards of human health and well-being, and with an aspiration to be the undisputed leader in healthcare technology, we need to prioritize sustainability to create a better world,” said Medtronic CEO Geoff Martha in the report. “Going forward, we will continue to invest in the ESG factors that are most aligned to our Mission while also driving long term growth and profitability. And we’ll act with a renewed purpose to operate as responsible corporate citizens — because it is the right thing to do.”
Promoting environmental stewardship: raising the bar
Because the health of the planet is vital to the health of society, we’ve stepped-up our efforts to reduce our global environmental footprint and protect the natural resources we rely on. In FY20 we:
Supporting a global workforce: inclusion, diversity, and equity
Today, more than ever, we're leaning into actions and policies that support global inclusion, diversity, and equity. We aspire to create a truly inclusive, diverse, and equitable workplace that fosters innovation and creativity, and where every employee feels a sense of belonging and well-being. In FY20, we:
Responding to COVID-19: a roadmap for change
The COVID-19 pandemic has placed extraordinary pressure on healthcare systems, communities, economies, and organizations of all sizes. Using our Mission as a roadmap, we mobilized to quickly respond to the pandemic. We provided vital access to our products and therapies, turned competitors into collaborators, and kept our employees safe as we worked together on behalf of patients around the world. Key steps we took in FY20 include:
As we look back on our FY20 highlights, we look forward to the future – with a renewed commitment to putting our purpose into action.